<DOC>
	<DOCNO>NCT02366468</DOCNO>
	<brief_summary>The purpose study demonstrate change best correct visual acuity ( BCVA ) comparable patient treat ranibizumab discretion investigator vs. treatment accord standard care scheme ( pro nata , need ) .</brief_summary>
	<brief_title>Study Efficacy Ranibizumab Different Regimens Patients With Diabetic Macula Edema</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients Type 1 Type 2 diabetes mellitus glycosylated hemoglobin ( HbA1c ) ≤ 12.0 % Patients visual impairment due DME least one eye BCVA ≥ 24 ≤ 78 letter study eye Active intraocular inflammation Any active infection either eye Structural damage within 0.5 disc diameter center macula study eye Uncontrolled glaucoma either eye screen Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Visual impairment</keyword>
</DOC>